Results 91 to 100 of about 458,798 (262)
Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer
Background The role of reactive oxygen species (ROS) in cancer is debated. One main antioxidant enzyme is mitochondrial superoxide dismutase (SOD2) which has been shown to influence tumor initiation and metastatic progression in several cancer types ...
Sankaranarayanan Ramasubramanian +5 more
doaj +1 more source
Molecular targeting of HPV oncogenes and oncogenic protein
TARA (Trinity’s Access to Research Archive) has a robust takedown policy.
openaire +1 more source
Model of circNrip1 (cNrip1) upregulation driving neuropathic pain mechanisms. After peripheral nerve injury, increased FUS triggers the formation and upregulation of cNrip1 in injured DRG neurons. Upregulated cNrip1 recruits SYNCRIP to the 3′‐UTR of Tlr2 mRNA by binding to both, thereby promoting SYNCRIP‐triggered Tlr2 mRNA stability and increasing ...
Xiaozhou Feng +14 more
wiley +1 more source
This study identifies palmitoylation as a novel regulatory modification of SMAD4, mediated by ZDHHC22/APT2. It activates fatty acid synthesis, creating a self‐reinforcing SMAD4–FASN–palmitate feedback loop that drives pancreatic cancer growth and enhances radiotherapy sensitivity.
Yang Wang +16 more
wiley +1 more source
The immunohistochemical expression of p53, c-erbB-2, and cathepsin D oncogene proteins was examined in 494 primary breast carcinomas. This study aimed to investigate an association of expression of these three proteins with other variables known to be ...
Supornpim Chearskul +4 more
doaj
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu +18 more
wiley +1 more source
Molecular Glue cc‐885 Inhibits VHL‐Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation
VHL‐deficient kidney cancer lacks effective treatments. This study reveals that the molecular glue degrader cc‐885 hijacks the cellular recycling system to selectively destroy the oncogenic protein ETS1, effectively killing VHL‐mutant tumors. Combining CC‐885 with the approved drug belzutifan achieves powerful synergy, offering a promising new ...
Taowei Yang +15 more
wiley +1 more source
The hyperactivation of PI3K/AKT signaling in PTEN wild‐type triple‐negative breast cancer represents a clinical paradox. We delineate a novel post‐translational regulatory axis wherein the oncogene TSPYL5 competitively antagonizes the deubiquitinase USP10.
Jiaying Shi +8 more
wiley +1 more source
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou +12 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source

